Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ono licenses allogenic CAR-T cell therapy from Celyad

Executive Summary

Celyad SA granted Ono Pharmaceutical Co. Ltd. exclusive rights to develop and sell its allogenic CAR T-cell therapy NKR2 for solid and blood cancers in Japan, South Korea, and Taiwan. Ono also gets an option to develop and sell autologous NKR2 in the same territories.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies